/PRNewswire/ In their most recent earnings call on October 29, 2021, Takeda revealed that discussions with the FDA have led to a potential approval for.
Regulation - US FDA, Dermatologicals, Denmark thepharmaletter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thepharmaletter.com Daily Mail and Mail on Sunday newspapers.
Amgen has agreed to co-develop and co-commercialize with Kyowa Kirin its Phase III-bound KHK4083, a potentially first-in-class treatment for atopic dermatitis, through a collaboration that could generate more than $1.2 billion for the Japanese pharma.
Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets
The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis) in multiple sclerosis, Stelara (Janssen) in ulcerative colitis, Tremfya (Janssen) in psoriatic arthritis, and Benlysta (GSK) and Lupkynis (Aurinia) in lupus nephritis
News provided by
Share this article
Share this article
EXTON, Pa., Jan. 29, 2021 /PRNewswire/ Spherix Global Insights, a leading market intelligence firm specializing in select dermatology, gastroenterology, nephrology, neurology, and rheumatology markets, announces the inaugural publications of their newest service offering,
Share this article
Share this article
EXTON, Pa., Jan. 20, 2021 /PRNewswire/ Two 2020 European Medical Agency (EMA) approvals, Takeda s Entyvio SC and Celltrion Healthcare s infliximab biosimilar, Remsima SC, have captured notable shares among EU5 IBD patients, according to Spherix s recent report,
RealTime Dynamix™: Inflammatory Bowel Disease (EU). The report sampled 246 EU5 gastroenterologists in November and December of 2020. While both new, subcutaneous market entrants have mostly gained prescribing momentum by cannibalizing their corresponding IV formulations, AbbVie s Humira stands out with its continual decline in EU5 IBD utilization.
Entyvio SC has managed to capture a sizeable portion of both the EU5 ulcerative colitis (UC) and Crohn s disease (CD) markets. This uptake is supported by the established familiarity that gastroenterologists have with Entyvio s IV formulation. Not surprisingly, Takeda is experiencing some cannibalization of Entyvio IV with the introdu